| 2026-04-13 |
详情>>
股本变动：
变动后总股本2478.74万股
|
| 2026-04-13 |
详情>>
业绩披露：
2026年中报每股收益-0.13美元,归母净利润-304.5万美元,同比去年增长43.79%
|
| 2026-03-17 |
详情>>
内部人交易：
BUNKA CHRISTOPHER股份减少100000.00股
|
| 2026-01-13 |
详情>>
业绩披露：
2026年一季报每股收益-0.07美元,归母净利润-159.5万美元,同比去年增长41.01%
|
| 2025-12-10 |
股东大会：
将于2026-01-27召开股东大会
会议内容 ▼▲
- 1.To elect the following seven Director nominees, Richard Christopher, John Docherty, Christopher Bunka, Nicholas Baxter, William Edward (Ted) McKechnie, Albert Reese Jr., and Bal Bhullar as Directors to serve our Company for the ensuing year or until their successors are elected;
2.To ratify the appointment of MaloneBailey LLP as our independent registered public accounting firm for the fiscal year ending August 31, 2026, and to allow the Directors to set the remuneration;
3.To ratify and approve all acts of the Directors, lawfully made, since the last shareholders’ meeting;
4.To transact such other business as may properly come before the Meeting or any adjournment of postponement thereof.
|
| 2025-11-28 |
详情>>
业绩披露：
2025年年报每股收益-0.66美元,归母净利润-1190.18万美元,同比去年增长-105.37%
|
| 2025-07-14 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.53美元,归母净利润-920.6万美元,同比去年增长-154.97%
|
| 2025-04-14 |
详情>>
业绩披露：
2025年中报每股收益-0.32美元,归母净利润-541.69万美元,同比去年增长-196.19%
|
| 2025-01-10 |
详情>>
业绩披露：
2025年一季报每股收益-0.16美元,归母净利润-270.37万美元,同比去年增长-129.26%
|
| 2024-11-27 |
股东大会：
将于2025-01-14召开股东大会
会议内容 ▼▲
- 1.To elect the following seven director nominees, John Docherty, Christopher Bunka, Nicholas Baxter, William Edward (Ted) McKechnie, Albert Reese Jr., Richard Christopher and Bal Bhullar as Directors to serve our Company for the ensuing year or until their successors are elected;
2.To ratify the appointment of MaloneBailey LLP as our independent registered public accounting firm for the fiscal year ending August 31, 2025, and to allow the Directors to set the remuneration;
3.To approve on a non-binding, advisory basis, the compensation of our named executive officers;
4.To approve, on a non-binding, advisory basis, the frequency of future advisory votes on the compensation of our named executive officers;
5.To approve, pursuant to Nasdaq listing rules, the issuance of up to an aggregate 4,608,209 share purchase warrants entitling the holders thereof to purchase up to 4,551,019 shares of common stock at an exercise price of $3.06 per share and up to 57,190 shares of common stock at an exercise price of $3.825 per share, to an institutional investor and designees of the placement agent in connection with our private placement offering that closed on October 16, 2024, that may be equal to or exceed 20% of our common stock outstanding before such offering (the “Warrant Exercise Proposal”).
6.To ratify and approve all acts of the Directors, lawfully made, since the last shareholders’ meeting;
7.To transact such other business as may properly come before the Meeting or any adjournment of postponement thereof.
|
| 2024-11-26 |
详情>>
业绩披露：
2024年年报每股收益-0.47美元,归母净利润-579.53万美元,同比去年增长13.05%
|
| 2024-07-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.32美元,归母净利润-361.06万美元,同比去年增长33.45%
|
| 2024-04-09 |
详情>>
业绩披露：
2024年中报每股收益-0.18美元,归母净利润-182.89万美元,同比去年增长40.12%
|
| 2024-03-06 |
股东大会：
将于2024-04-23召开股东大会
会议内容 ▼▲
- 1.To elect the following six director nominees, John Docherty, Christopher Bunka, William (Ted) McKechnie, Nicholas Baxter, Albert Reese Jr. and Dr. Catherine C. Turkel as Directors to serve our Company for the ensuing year or until their successors are elected;
2.To ratify the appointment of MaloneBailey LLP as our independent registered public accounting firm for the fiscal year ending August 31, 2024, and to allow the Directors to set the remuneration;
3.To ratify and approve all acts of the Directors, lawfully made, since the last shareholders’ meeting;
4.To transact such other business as may properly come before the Meeting or any adjournment of postponement thereof.
|
| 2024-01-12 |
详情>>
业绩披露：
2024年一季报每股收益-0.13美元,归母净利润-117.93万美元,同比去年增长32.84%
|
| 2023-08-23 |
股东大会：
将于2023-10-10召开股东大会
会议内容 ▼▲
- 1.To approve a reverse stock split of the Company’s issued and outstanding common stock, but not of its authorized share capital, on the basis of a ratio range from 1-for-2 to 1-for-12, to be determined, at the discretion of the board of directors, or to not be effected at all as determined by the board of directors, for the purposes of ensuring the Lexaria’s continuance on the Nasdaq Capital Market and/or to encourage further investment in the Company so that it can proceed with its research programs, with any effected reverse stock split occurring by May 31, 2024;
2.To approve the adjournment of the Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there is insufficient votes in favour of Proposal No. 1 or to establish quorum.
|
| 2023-03-22 |
股东大会：
将于2023-05-09召开股东大会
会议内容 ▼▲
- 1.To elect the following six director nominees, John Docherty, Christopher Bunka, William (Ted) McKechnie, Nicholas Baxter, Albert Reese Jr. and Catherine C. Turkel as Directors to serve our Company for the ensuing year or until their successors are elected;
2.To ratify the appointment of as our independent registered public accounting firm for the fiscal year ending August 31, 2023 and to allow Directors to set the remuneration;
3.To approve a one-time repricing of certain issued stock options that currently have an exercise price ranging from 50% to 200% more than the current fair market value of the Company’s shares, as more particularly outlined in Proposal 3;
4.To approve an amendment to the Lexaria Bioscience Corp. Equity Incentive Plan (as approved by shareholders initially on June 20, 2019 and amended on June 28, 2021 – the “Incentive Plan”) to increase the maximum number of securities issuable from 510,433 securities to such greater number as is equal to 10% of the Company’s issued share capital as at May 31, 2023, being the last day of the month in which approval is being requested, all as more particularly outlined in Proposal 4;
5.To approve an amendment to the Incentive Plan to incorporate an evergreen formula whereby the maximum number of securities issuable under the Incentive Plan will increase annually on January 1, of each year starting with the 2024 year, to an amount equal to 10% of the Company’s issued share capital, all as more particularly outlined in Proposal 5;
6.To ratify and approve all acts of the Directors, lawfully made, since the last shareholders’ meeting;
7.To transact such other business as may properly come before the Meeting or any adjournment of postponement thereof.
|
| 2022-04-15 |
复牌提示：
2022-04-14 09:38:47 停牌，复牌日期 2022-04-14 09:43:47
|
| 2022-04-13 |
股东大会：
将于2022-05-31召开股东大会
会议内容 ▼▲
- 1.to elect the following five director nominees, John Docherty, Christopher Bunka, William (Ted) McKechnie, Nicholas Baxter and Albert Reese Jr. as Directors to serve our Company for the ensuing year or until their successors are elected;
2.to ratify the appointment of as our independent registered public accounting firm for the fiscal year ending August 31, 2022 and to allow Directors to set the remuneration;
3.to approve, on a non-binding, advisory basis, the compensation of our named executive officers;
4.to ratify and approve all acts of the Directors, lawfully made, since the last shareholders' meeting;
5.to transact such other business as may properly come before the Meeting or any adjournment of postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-05-14 |
股东大会：
将于2021-06-28召开股东大会
会议内容 ▼▲
- 1.to elect John Docherty, Christopher Bunka, William (Ted) McKechnie, Nicholas Baxter and Albert Reese Jr. as Directors to serve our Company for the ensuing year or until their successors are elected;
2.to ratify the appointment of as our independent registered public accounting firm for the fiscal year ending August 31, 2021 and to allow Directors to set the remuneration;
3.to approve the issuance of an additional 249,143 common shares pursuant to the exercise of stock awards issued under the Company’s Equity Incentive Plan as originally approved by the shareholders on June 20, 2019, so that the aggregate number of shares issued under such plan equals 10% of the Company’s current issued share capital.
4.to ratify and approve all acts of the Directors, lawfully made, since the last shareholders’meeting;
5.to transact such other business as may properly come before the Meeting or any adjournment of postponement thereof.
|